↓ Skip to main content

p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition

Overview of attention for article published in Molecular Cancer Therapeutics, September 2022
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
1 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition
Published in
Molecular Cancer Therapeutics, September 2022
DOI 10.1158/1535-7163.mct-21-0770
Pubmed ID
Authors

Felix Oppel, Senyao Shao, Sarah Gendreizig, Mark W. Zimmerman, Matthias Schürmann, Viyof Ful Flavian, Peter Goon, Susan N. Chi, Jon C. Aster, Holger Sudhoff, A. Thomas Look

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 1 Mendeley reader of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 1 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 1 100%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 1 100%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2022.
All research outputs
#13,305,659
of 22,579,714 outputs
Outputs from Molecular Cancer Therapeutics
#2,744
of 3,855 outputs
Outputs of similar age
#150,533
of 342,995 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#15
of 26 outputs
Altmetric has tracked 22,579,714 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,855 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,995 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.